BRAF and acute myeloid leukemia: In line with their findings, we observed that the BRAF-mutated AML patients exhibited an extremely poor prognosis compared to those without BRAF mutations, regardless of whether they had de novo AML or secondary AML, the specific subtypes of BRAF mutation, or the different chemotherapy regimens.